Navigation Links
Sensitivity Enhancements to Monogram's Trofile(TM) Assay Demonstrate Improved Power to Select Patients for CCR5 Antagonist Therapy
Date:6/16/2008

ted cancer therapeutics. More information about the Company and its technology can be found on its web site at http://www.monogrambio.com.

Forward Looking Statements

Certain statements in this press release are forward-looking. These forward-looking statements include references to the demand for our Trofile Assay, the potential use of our Trofile Assay for patient selection for Selzentry , or other CCR5 inhibitors, the size and timing of clinical trials utilizing our products, the outlook for Selzentry and our Trofile Assay, expected protection provided by patents and possible regulation of Trofile and our other products by the FDA. These forward-looking statements are subject to risks and uncertainties and other factors, which may cause actual results to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that physicians may not use a molecular diagnostic for patient selection for Selzentry or other HIV drugs; risks related to the implementation of the collaboration with Pfizer; risks and uncertainties relating to the performance of our products; the growth in revenues; the size, timing and success or failure of any clinical trials for CCR5 inhibitors, entry inhibitors or integrase inhibitors; the risk that our Trofile Assay may not be utilized for patient use with Selzentry and other CCR5 inhibitors; our ability to successfully conduct clinical studies and the results obtained from those studies; whether larger confirmatory clinical studies will confirm the results of initial studies; our ability to establish reliable, high-volume operations at commercially reasonable costs; expected reliance on a few customers for the majority of our revenues; the annual renewal of certain customer agreements; actual market acceptance of our products and adoption of our technolo
'/>"/>

SOURCE Monogram Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Agendia Acquires Rights to the Discovery of a Major Drug Resistance Mechanism in Breast Cancer Potentially Leading to a Herceptin(R) Sensitivity Test
2. ANX-514 Reduces Hypersensitivity Reactions Without Impacting Pharmacokinetics or Antitumor Activity in Preclinical Tests
3. Data Presented on Monogram HIV Tropism Tests at Retrovirus Conference sets New Standards of Assay Sensitivity
4. New Dual Cold Probe From Varian, Inc. Increases Sensitivity and Reduces Analysis Times for 13C NMR Experiments
5. Olympus FluoroPoint(TM) System Provides High-Sensitivity Single Molecule and Protein Interaction Analysis for Screening and Research
6. Study Reaffirms Superiority of Trofile(TM) Assay
7. New York Medicaid Program Establishes Coverage for Trofile(TM)
8. Caliper Life Sciences Introduces High Throughput RNA Assay to Improve Workflow in Gene Expression Studies
9. ProImmune Launches New MHC-Peptide Binding Assay for Class II HLA Alleles
10. Assay Designs(TM) Announces Additions to the Leadership Team
11. MedAssets Supply Chain Systems Selects Siemens Medical Solutions Diagnostics for Chemistry, Automation and Immunoassay Solutions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... ... 27, 2015 , ... Inc. Magazine released its annual list of the 5,000 ... in growth for the three years through 2014. Being named to the Inc. 5000 ... in the country. , “We are thrilled to make the Inc. 5000 list ...
(Date:8/26/2015)... - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ICO) ... quarter ended June 30, 2015. Amounts, unless specified ... under International Financial Reporting Standards ("IFRS"). ... Oral Amp B program, rapidly advancing towards the ... Rae , President & CEO of iCo Therapeutics. "We ...
(Date:8/26/2015)... -- Intrexon Corporation (NYSE: XON ), a leader ... previously announced public offering of common stock, including the ... to purchase an additional 731,707 shares of common stock ...  The exercise of the underwriters, option brought the total ... to 5,609,756 shares and increased the total gross proceeds ...
(Date:8/26/2015)... San Bruno, CA. (PRWEB) , ... August 26, 2015 , ... ... three major conferences to develop new business relationships with local sponsors in southern California. ... services to facilitate their drug development processes and regulatory pathways., , ...
Breaking Biology Technology:iLab Solutions Named to 2015 Inc. 5000 List 2iLab Solutions Named to 2015 Inc. 5000 List 3iCo Therapeutics Announces Second Quarter 2015 Financial Results 2iCo Therapeutics Announces Second Quarter 2015 Financial Results 3Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 2Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 3Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 4PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 2PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 3
... ... C completes ... - Rights to TRAIL receptor antibodies reacquired - ... development for the treatment of atherosclerosis -, ROCKVILLE, Md., May 5 Human ...
... EDMONTON, May 5 /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX: ... (MS), will hold,its Annual General Meeting on Friday, May ... A live audio webcast of the conference call will ... ten minutes prior to the,conference call to ensure adequate ...
... Cequent Pharmaceuticals, a,pioneer in the development ... prevent and treat human disease, announced that ... board of directors. Dr. Taylor is,president and ... a,Cambridge, Massachusetts-based biotechnology company developing novel,classes of ...
Cached Biology Technology:Human Genome Sciences Announces First Quarter 2008 Financial Results and Key Developments 2Human Genome Sciences Announces First Quarter 2008 Financial Results and Key Developments 3Human Genome Sciences Announces First Quarter 2008 Financial Results and Key Developments 4Human Genome Sciences Announces First Quarter 2008 Financial Results and Key Developments 5Human Genome Sciences Announces First Quarter 2008 Financial Results and Key Developments 6Human Genome Sciences Announces First Quarter 2008 Financial Results and Key Developments 7Human Genome Sciences Announces First Quarter 2008 Financial Results and Key Developments 8Human Genome Sciences Announces First Quarter 2008 Financial Results and Key Developments 9BioMS Medical announces conference call and web cast for Annual General Meeting 2Michael D. Taylor, Ph.D., Joins Cequent Pharmaceuticals' Board of Directors 2
(Date:8/6/2015)... BOSTON and TELTOW, Germany ... the 2015 Siggraph Conference, SensoMotoric Instruments (SMI) ... augmented reality , based on Epson,s Moverio ... eye tracking platform. With this new solution, unprecedented quality ... multi-modal, hands-free interaction with context-sensitive displays. For the first ...
(Date:8/5/2015)... Calif. , Aug. 5, 2015 The ... continuous growth in applications, penetration into newer sectors, and ... year. The global biosensors space has seen the entry ... the market so far. (Photo - ... & Sullivan, Analysis of the Global Biosensors Market ...
(Date:7/31/2015)... 2015 Den 10. internationale konference om Genomik ... 22. - 25. oktober i Shenzhen ... fødselsdag i år. Siden starten i 2006 er ICB ... ,omik,-feltet, og er en af de mest dynamiske, entusiastiske ... på nylige gennembrud og fremskridt inden for ,omik,-forskning, som ...
Breaking Biology News(10 mins):SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 3Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2
... spend eating meals together has been linked to the ... who eat together regularly reporting declines in substance abuse, ... a new study that looks at children with asthma ... mealtime affected the children,s health. The study appears ...
... PORTLAND, Ore. -- The pediatric cardiac team at Oregon ... first in the region and one of a handful ... without open-heart surgery. To date, four patients have ... Adult Congenital Cardiac Catheterization Lab. All reported immediate improvement ...
... Bar Harbor, Maine Researchers at Dana-Farber Cancer Institute ... have identified a regulatory defect that drives lupus. ... to systemic lupus erythematosus-like autoimmune disease," the researchers state ... of the National Academy of Sciences . The research ...
Cached Biology News:Family mealtimes play a role in health of children with asthma 2OHSU fixes complex heart problems without open-heart surgery 2New clue to lupus: Failed autoimmune suppression mechanism 2
...
Anti Autotaxin /ENPP2 , - (Rabbit)...
...
... An N-nitroso-containing diabetogenic compound that acts ... pancreatic islets. An antibiotic effective against ... DNA strand breaks in pancreatic islet ... in H 2 O. RTECS LZ5775000, ...
Biology Products: